Platform-derived Program(s)

About Immuto Scientific

Immuto Scientific is a private, pre-clinical stage biotech targeting cancer through a revolutionary focus on disease-specific Surface Protein Conformations (SPCs). Its core asset is a patented, integrated platform combining native-state structural proteomics, ultrasensitive mass spectrometry, and AI/ML to discover novel, targetable epitopes with high disease specificity. The company is pre-revenue and appears to be in the platform validation and early pipeline development phase, positioning itself to unlock a new class of precision therapeutics against previously undruggable targets.

About Diadem Biotherapeutics

Diadem Biotherapeutics is a private, pre-clinical stage biotech leveraging engineered extracellular vesicles as a novel drug delivery and cell communication modality. The company's core technology, the DECOSTAR™ platform, bioengineers EVs to precisely activate or repress immune receptors, aiming to access validated immunotherapy targets for oncology and autoimmunity. Founded by a team of bioengineers and drug developers, Diadem is backed by venture capital and is developing a pipeline of potential first-in-class therapeutics, though it remains pre-revenue and in the early research phase.

Therapeutic Areas

Other Oncology (unspecified) Drugs